董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Wenzhao Lu | 男 | Chairman of the Board and Director | 68 | 10.00万美元 | 12.57 | 2026-07-13 |
| Steven A. Sanders | 男 | Lead Independent Director | 80 | 7.12万美元 | 1.01 | 2026-07-13 |
| Lourdes Felix | 女 | Director | 58 | 7.12万美元 | 0.51 | 2026-07-13 |
| Michael Mathews | 男 | Director | 64 | 0.25万美元 | 0.81 | 2026-07-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Meng Li | 女 | Chief Operating Officer and Interim Chief Executive Officer and Secretary | 48 | 19.17万美元 | 2.18 | 2026-07-13 |
| Sam Knipper | 男 | Chief Financial Officer | 31 | 未披露 | 0.88 | 2026-07-13 |
| Luisa Ingargiola | 女 | Chief Strategy Officer | 58 | 52.50万美元 | 2.08 | 2026-07-13 |
董事简历
中英对照 | 中文 | 英文- Wenzhao Lu
-
Wenzhao Lu是我们的董事长。他是一位经验丰富的梦百合企业家，在中国拥有丰富的运营知识和经验。2010年以来，他一直担任the Daopei Medical Group（DPMG）的董事会主席。在他的领导下，DPMG最近扩大了其临床网络，涉及武汉Biolake最先进的干细胞库、位于北京、上海和河北的三家顶级私人医院、专科血液学实验室以及血液学研究所，在中国有100多家合作和协作医院。DPMG由中国著名造血干细胞移植开拓者、工程院院士陆道培教授创立。Wenzhao Lu先生于1988年在天普大学泰勒艺术学院获得文学学士学位，随后在奥美广告公司担任高级艺术总监。在加入DPMG之前，陆先生于2009年担任BioTime Asia Limited的首席运营官，该公司是BioTime，Inc.（NYSE American:BTX）的子公司。
Wenzhao Lu has served as Chairman of the Board since October 10, 2016. He is a seasoned healthcare entrepreneur with extensive operational knowledge and experience in the U.S. and Asia. He served as chairman of the board of directors of the Daopei Medical Group ("DPMG") from 2010 to 2021. Under his leadership, DPMG operated three top ranked private hospitals (located in Beijing and Hebei), specialty hematology laboratories, and a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and a member of the Academy of Engineering in China. Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. In 2009, prior to joining DPMG, Mr. Lu served as Chief Operating Officer of BioTime Asia Limited, a subsidiary of BioTime, Inc. (NYSE American: BTX). - Wenzhao Lu是我们的董事长。他是一位经验丰富的梦百合企业家，在中国拥有丰富的运营知识和经验。2010年以来，他一直担任the Daopei Medical Group（DPMG）的董事会主席。在他的领导下，DPMG最近扩大了其临床网络，涉及武汉Biolake最先进的干细胞库、位于北京、上海和河北的三家顶级私人医院、专科血液学实验室以及血液学研究所，在中国有100多家合作和协作医院。DPMG由中国著名造血干细胞移植开拓者、工程院院士陆道培教授创立。Wenzhao Lu先生于1988年在天普大学泰勒艺术学院获得文学学士学位，随后在奥美广告公司担任高级艺术总监。在加入DPMG之前，陆先生于2009年担任BioTime Asia Limited的首席运营官，该公司是BioTime，Inc.（NYSE American:BTX）的子公司。
- Wenzhao Lu has served as Chairman of the Board since October 10, 2016. He is a seasoned healthcare entrepreneur with extensive operational knowledge and experience in the U.S. and Asia. He served as chairman of the board of directors of the Daopei Medical Group ("DPMG") from 2010 to 2021. Under his leadership, DPMG operated three top ranked private hospitals (located in Beijing and Hebei), specialty hematology laboratories, and a hematology research institute, with more than 100 partnering and collaborating hospitals in China. DPMG was founded by Professor Daopei Lu, a renowned hematologist pioneering in hematopoietic stem cell transplant and a member of the Academy of Engineering in China. Mr. Lu received a Bachelor of Arts from Temple University Tyler School of Arts in 1988 and subsequently worked as senior Art Director at Ogilvy & Mather Advertising Company. In 2009, prior to joining DPMG, Mr. Lu served as Chief Operating Officer of BioTime Asia Limited, a subsidiary of BioTime, Inc. (NYSE American: BTX).
- Steven A. Sanders
-
StevenA.Sanders是董事会成员之一。自2017年1月以来，桑德斯先生一直担任Ortoli Rosenstadt LLP律师事务所的法律顾问。从2007年7月至2017年1月，桑德斯先生是Ortoli Rosenstadt LLP的高级合伙人。从2004年1月1日到2007年6月30日，他曾担任Rubin，Bailin，Ortoli，LLP的律师事务所的法律顾问。2001年1月1日至2003年12月31日，他是律师事务所Spitzer&Feldman PC的法律顾问。桑德斯先生还担任Helijet International，Inc.和Electrameccanica VehiclesCorp.的董事纳斯达克股票代码:SOLO。此外，他自2013年10月起担任美国戏剧艺术学院（American Academy of Dramatic Arts）的董事，自2015年2月起担任贝街剧院（Bay Street Theater）的董事。Sanders先生在康奈尔大学（Cornell University）获得法学博士学位，在纽约城市学院（City College of New York）获得工商管理学士学位。
Steven A. Sanders has served as a member of the Board since July 30, 2018 and was appointed as Avalon Globocare Corp's lead independent director effective as of February 24, 2026. Since January 2017, Mr. Sanders has been Of Counsel to the law firm of Ortoli Rosenstadt LLP. From July 2007 until January 2017, Mr. Sanders was a Senior Partner at Ortoli Rosenstadt LLP. From January 1, 2004 until June 30, 2007, he was Of Counsel to the law firm of Rubin, Bailin, Ortoli, LLP. From January 1, 2001 to December 31, 2003, he was Counsel at the law firm of Spitzer & Feldman PC. Mr. Sanders also serves as a member of the board of directors of Blueport Acquisition Ltd (Nasdaq: BPAC) and Helijet International, Inc. From March 2018 to January 2024, he also served as a director of ElectraMeccanica Vehicles Corp., previously a Nasdaq listed company. Additionally, since October 2013, he has been a member of the board of directors at the American Academy of Dramatic Arts, and, since February 2015, has been a member of the board of directors of the Bay Street Theater. Mr. Sanders received his JD from Cornell University and his BBA from The City College of New York. - StevenA.Sanders是董事会成员之一。自2017年1月以来，桑德斯先生一直担任Ortoli Rosenstadt LLP律师事务所的法律顾问。从2007年7月至2017年1月，桑德斯先生是Ortoli Rosenstadt LLP的高级合伙人。从2004年1月1日到2007年6月30日，他曾担任Rubin，Bailin，Ortoli，LLP的律师事务所的法律顾问。2001年1月1日至2003年12月31日，他是律师事务所Spitzer&Feldman PC的法律顾问。桑德斯先生还担任Helijet International，Inc.和Electrameccanica VehiclesCorp.的董事纳斯达克股票代码:SOLO。此外，他自2013年10月起担任美国戏剧艺术学院（American Academy of Dramatic Arts）的董事，自2015年2月起担任贝街剧院（Bay Street Theater）的董事。Sanders先生在康奈尔大学（Cornell University）获得法学博士学位，在纽约城市学院（City College of New York）获得工商管理学士学位。
- Steven A. Sanders has served as a member of the Board since July 30, 2018 and was appointed as Avalon Globocare Corp's lead independent director effective as of February 24, 2026. Since January 2017, Mr. Sanders has been Of Counsel to the law firm of Ortoli Rosenstadt LLP. From July 2007 until January 2017, Mr. Sanders was a Senior Partner at Ortoli Rosenstadt LLP. From January 1, 2004 until June 30, 2007, he was Of Counsel to the law firm of Rubin, Bailin, Ortoli, LLP. From January 1, 2001 to December 31, 2003, he was Counsel at the law firm of Spitzer & Feldman PC. Mr. Sanders also serves as a member of the board of directors of Blueport Acquisition Ltd (Nasdaq: BPAC) and Helijet International, Inc. From March 2018 to January 2024, he also served as a director of ElectraMeccanica Vehicles Corp., previously a Nasdaq listed company. Additionally, since October 2013, he has been a member of the board of directors at the American Academy of Dramatic Arts, and, since February 2015, has been a member of the board of directors of the Bay Street Theater. Mr. Sanders received his JD from Cornell University and his BBA from The City College of New York.
- Lourdes Felix
-
Lourdes Felix，被任命为公司董事会成员，自2024年4月起生效。Felix女士是一位企业家和企业财务主管，在资本市场、公共会计和私营部门拥有30年的综合经验。她目前担任BioCorRx Inc.（OTCQB：BICX）的首席执行官、首席财务官以及董事会成员，该公司专注于成瘾治疗解决方案和相关疾病。自2012年10月起任职于BioCorRx。Felix女士是BioCorRx Pharmaceuticals Inc.的创始人之一和总裁，BioCorRx Pharmaceuticals Inc.是BioCorRx Inc.的控股子公司。在加入BioCorRx之前，她的工作经验是私营部门和公共会计。自2021年10月以来，Felix女士一直担任Siyata Mobile，Inc.（纳斯达克：SYTA）的董事会成员、独立董事、审计委员会主席以及薪酬委员会和提名与公司治理委员会成员。自2023年1月9日以来，Felix女士还一直担任Avalon GloboCare Corp.（纳斯达克：ALBT）的董事会成员、独立董事和薪酬委员会主席。Felix女士在财务、会计、全公司运营、预算编制和内部控制原则（包括GAAP、SEC和萨班斯-奥克斯利法案合规）方面拥有专长。她对联邦和州法规了如指掌，并成功管理和制作了SEC监管文件。她在发展和管理金融业务方面也有丰富的经验。Felix女士拥有凤凰城大学会计学理学学士学位。她也是东北大学D'Amore-McKim商学院的MBA候选人。
Lourdes Felix has served as a director of the Company since 2023. Lourdes Felix is a Hispanic entrepreneur and seasoned executive with over 30 years of experience in management, corporate finance, capital markets, public accounting, and the private sector including 15 years in executive leadership. She currently serves as CEO, CFO, and Director of BioCorRx Inc. (OTCQB: BICX), a biotechnology company specializing in addiction treatment solutions.A founding member and President of BioCorRx Pharmaceuticals Inc., she oversees commercialization and development of addiction and related disorder treatments, regulatory recruitment, strategic planning, and M&A activities. Lourdes led the launch of UnCraveRx, a weight loss program introduced in 2019, and in 2025, negotiated the company's acquisition of its first FDA approved drug, LUCEMYRA (lofexidine).Known for her strategic financial leadership, she has secured over $40 million in equity and non diluive funding, and has extensive experience in SEC reporting, compliance, and risk management. Prior to BioCorRx, she worked in public accounting and the private sector, with deep expertise in GAAP, SEC, and SOX compliance, financial operations, and internal controls.Since 2023 to the present, Ms. Felix has served as a Board Member and Compensation Committee Chair of Avalon GloboCare Corporation (NASDAQ: ALBT), and from 2024 to the present as a Board Member and Audit Committee Chair of La Rosa Holdings Corp. (NASDAQ: LRHC). - Lourdes Felix，被任命为公司董事会成员，自2024年4月起生效。Felix女士是一位企业家和企业财务主管，在资本市场、公共会计和私营部门拥有30年的综合经验。她目前担任BioCorRx Inc.（OTCQB：BICX）的首席执行官、首席财务官以及董事会成员，该公司专注于成瘾治疗解决方案和相关疾病。自2012年10月起任职于BioCorRx。Felix女士是BioCorRx Pharmaceuticals Inc.的创始人之一和总裁，BioCorRx Pharmaceuticals Inc.是BioCorRx Inc.的控股子公司。在加入BioCorRx之前，她的工作经验是私营部门和公共会计。自2021年10月以来，Felix女士一直担任Siyata Mobile，Inc.（纳斯达克：SYTA）的董事会成员、独立董事、审计委员会主席以及薪酬委员会和提名与公司治理委员会成员。自2023年1月9日以来，Felix女士还一直担任Avalon GloboCare Corp.（纳斯达克：ALBT）的董事会成员、独立董事和薪酬委员会主席。Felix女士在财务、会计、全公司运营、预算编制和内部控制原则（包括GAAP、SEC和萨班斯-奥克斯利法案合规）方面拥有专长。她对联邦和州法规了如指掌，并成功管理和制作了SEC监管文件。她在发展和管理金融业务方面也有丰富的经验。Felix女士拥有凤凰城大学会计学理学学士学位。她也是东北大学D'Amore-McKim商学院的MBA候选人。
- Lourdes Felix has served as a director of the Company since 2023. Lourdes Felix is a Hispanic entrepreneur and seasoned executive with over 30 years of experience in management, corporate finance, capital markets, public accounting, and the private sector including 15 years in executive leadership. She currently serves as CEO, CFO, and Director of BioCorRx Inc. (OTCQB: BICX), a biotechnology company specializing in addiction treatment solutions.A founding member and President of BioCorRx Pharmaceuticals Inc., she oversees commercialization and development of addiction and related disorder treatments, regulatory recruitment, strategic planning, and M&A activities. Lourdes led the launch of UnCraveRx, a weight loss program introduced in 2019, and in 2025, negotiated the company's acquisition of its first FDA approved drug, LUCEMYRA (lofexidine).Known for her strategic financial leadership, she has secured over $40 million in equity and non diluive funding, and has extensive experience in SEC reporting, compliance, and risk management. Prior to BioCorRx, she worked in public accounting and the private sector, with deep expertise in GAAP, SEC, and SOX compliance, financial operations, and internal controls.Since 2023 to the present, Ms. Felix has served as a Board Member and Compensation Committee Chair of Avalon GloboCare Corporation (NASDAQ: ALBT), and from 2024 to the present as a Board Member and Audit Committee Chair of La Rosa Holdings Corp. (NASDAQ: LRHC).
- Michael Mathews
-
Michael Mathews自2007年8月起担任董事，2007年6月-2011年1月担任首席执行官。他也在5to1股份有限公司（5to1 Inc.，一家上市的出版商控制的在线广告联盟）的董事会工作。在interclick之前（2004-2007年），他担任World Avenue U.S.A.有限责任公司（World Avenue U.S.A., LLC，一家网络营销公司）的营销和出版商服务高级副总裁。Mathews先生被选为董事是出于他在interclick的知识深度，包括它的运营、战略、在互联网营销行业的丰富知识。
Michael Mathews has served as a member of the Board since December 2025. Mr. Mathews has served as Chairman and Chief Executive Officer of Aspen Group, Inc. (OTCQB: ASPU) since March 2012. He served as Chief Executive Officer of Interclick, Inc. (Nasdaq: ICLK) from August 2007 until January 2011. Mr. Mathews also served as a Director of Interclick from June 2007 until it was acquired by Yahoo, Inc. (Nasdaq: YHOO) in December 2011. From 2004 to 2007, Mr. Mathews served as the senior vice president of marketing and publisher services for World Avenue U.S.A., LLC, an Internet promotional marketing company. - Michael Mathews自2007年8月起担任董事，2007年6月-2011年1月担任首席执行官。他也在5to1股份有限公司（5to1 Inc.，一家上市的出版商控制的在线广告联盟）的董事会工作。在interclick之前（2004-2007年），他担任World Avenue U.S.A.有限责任公司（World Avenue U.S.A., LLC，一家网络营销公司）的营销和出版商服务高级副总裁。Mathews先生被选为董事是出于他在interclick的知识深度，包括它的运营、战略、在互联网营销行业的丰富知识。
- Michael Mathews has served as a member of the Board since December 2025. Mr. Mathews has served as Chairman and Chief Executive Officer of Aspen Group, Inc. (OTCQB: ASPU) since March 2012. He served as Chief Executive Officer of Interclick, Inc. (Nasdaq: ICLK) from August 2007 until January 2011. Mr. Mathews also served as a Director of Interclick from June 2007 until it was acquired by Yahoo, Inc. (Nasdaq: YHOO) in December 2011. From 2004 to 2007, Mr. Mathews served as the senior vice president of marketing and publisher services for World Avenue U.S.A., LLC, an Internet promotional marketing company.
高管简历
中英对照 | 中文 | 英文- Meng Li
Meng Li是我们的首席运营官和秘书，也是前董事会成员。李女士在国际营销，品牌，传播和媒体投资咨询方面拥有超过15年的执行经验。她曾担任Maxus/Groupm公司（WPP Group Company）的董事总经理，在那里她曾负责业务P&L和公司管理（从2006年到2015年）。在加入Maxus/Group M之前，李女士于2000年至2006年在Zenith Media（一家阳狮集团公司）工作，担任高级经理。李女士在中国大连海事大学（Dalian Maritime University）获得国际经济法文学学士学位。
Meng Li has served as Interim Chief Executive Officer since November 30, 2025 and served as Avalon Globocare Corp's Chief Operating Officer and Secretary since October 10, 2016 and served as a member of the Board from October 10, 2016 to July 9, 2018 and from April 5, 2019 through December 30, 2022. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.- Meng Li是我们的首席运营官和秘书，也是前董事会成员。李女士在国际营销，品牌，传播和媒体投资咨询方面拥有超过15年的执行经验。她曾担任Maxus/Groupm公司（WPP Group Company）的董事总经理，在那里她曾负责业务P&L和公司管理（从2006年到2015年）。在加入Maxus/Group M之前，李女士于2000年至2006年在Zenith Media（一家阳狮集团公司）工作，担任高级经理。李女士在中国大连海事大学（Dalian Maritime University）获得国际经济法文学学士学位。
- Meng Li has served as Interim Chief Executive Officer since November 30, 2025 and served as Avalon Globocare Corp's Chief Operating Officer and Secretary since October 10, 2016 and served as a member of the Board from October 10, 2016 to July 9, 2018 and from April 5, 2019 through December 30, 2022. Ms. Li has over 15 years of executive experience in international marketing, branding, communications, and media investment consultancy. Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenith Media (a Publicis Group company) from 2000 to 2006 as Senior Manager. Ms. Li received a Bachelor of Arts in International Economic Law from Dalian Maritime University in China.
- Sam Knipper
Sam Knipper，即Knipper先生，自2026年6月3日起担任公司首席财务官。自2023年10月起，Knipper先生在Brio Financial Group担任SEC报告经理，自2024年10月起为上市公司和私营公司提供外包CFO和财务报告服务，包括为一家人工智能公司提供服务。在担任这一职务期间，他就SEC合规和报告事宜向几家特殊目的收购公司（SPAC）提供建议，监督注册声明、季度和年度报告以及其他上市公司文件的准备工作。从2021年7月到2023年10月，Knipper先生是Calabrese Consulting的高级助理，在那里他为SPAC和新兴公司提供外包CFO服务。他管理财务报告流程，维护会计记录，与审计师和法律顾问协调，并通过季度和年度报告周期为客户提供支持。从2020年11月到2021年5月，Knipper先生在Cantor Fitzgerald担任SEC报告助理，负责编制和分析财务报表并支持公司的年度和季度报告流程。从2017年10月到2020年11月，Knipper先生在毕马威会计师事务所工作，最近担任高级审计助理，领导银行、资本市场和汽车租赁领域的上市公司和私营公司的审计工作。
Sam Knipper has served as the Company's Chief Financial Officer since June 3, 2026. Since October 2023, Mr. Knipper has served as an SEC Reporting Manager at Brio Financial Group, where he provides outsourced CFO and financial reporting services to both public and private companies, including for an AI company since October 2024. In this role, he advises several Special Purpose Acquisition Companies (SPACs) on SEC compliance and reporting matters, overseeing the preparation of registration statements, quarterly and annual reports, and other public company filings. From July 2021 through October 2023, Mr. Knipper was a Senior Associate at Calabrese Consulting, where he provided outsourced CFO services to SPACs and emerging companies. He managed financial reporting processes, maintained accounting records, coordinated with auditors and legal counsel, and supported clients through quarterly and annual reporting cycles. From November 2020 through May 2021, Mr. Knipper served as an SEC Reporting Associate at Cantor Fitzgerald, where he was responsible for preparing and analyzing financial statements and supporting the company's annual and quarterly reporting processes and from October 2017 through November 2020, Mr. Knipper worked at KPMG, most recently in the role of Senior Audit Associate and led audit engagements for both public and private companies in the banking, capital markets, and automotive leasing sectors. Mr. Knipper holds a Bachelor of Science in Business Administration and Accounting and a Master of Accountancy from Rider University.- Sam Knipper，即Knipper先生，自2026年6月3日起担任公司首席财务官。自2023年10月起，Knipper先生在Brio Financial Group担任SEC报告经理，自2024年10月起为上市公司和私营公司提供外包CFO和财务报告服务，包括为一家人工智能公司提供服务。在担任这一职务期间，他就SEC合规和报告事宜向几家特殊目的收购公司（SPAC）提供建议，监督注册声明、季度和年度报告以及其他上市公司文件的准备工作。从2021年7月到2023年10月，Knipper先生是Calabrese Consulting的高级助理，在那里他为SPAC和新兴公司提供外包CFO服务。他管理财务报告流程，维护会计记录，与审计师和法律顾问协调，并通过季度和年度报告周期为客户提供支持。从2020年11月到2021年5月，Knipper先生在Cantor Fitzgerald担任SEC报告助理，负责编制和分析财务报表并支持公司的年度和季度报告流程。从2017年10月到2020年11月，Knipper先生在毕马威会计师事务所工作，最近担任高级审计助理，领导银行、资本市场和汽车租赁领域的上市公司和私营公司的审计工作。
- Sam Knipper has served as the Company's Chief Financial Officer since June 3, 2026. Since October 2023, Mr. Knipper has served as an SEC Reporting Manager at Brio Financial Group, where he provides outsourced CFO and financial reporting services to both public and private companies, including for an AI company since October 2024. In this role, he advises several Special Purpose Acquisition Companies (SPACs) on SEC compliance and reporting matters, overseeing the preparation of registration statements, quarterly and annual reports, and other public company filings. From July 2021 through October 2023, Mr. Knipper was a Senior Associate at Calabrese Consulting, where he provided outsourced CFO services to SPACs and emerging companies. He managed financial reporting processes, maintained accounting records, coordinated with auditors and legal counsel, and supported clients through quarterly and annual reporting cycles. From November 2020 through May 2021, Mr. Knipper served as an SEC Reporting Associate at Cantor Fitzgerald, where he was responsible for preparing and analyzing financial statements and supporting the company's annual and quarterly reporting processes and from October 2017 through November 2020, Mr. Knipper worked at KPMG, most recently in the role of Senior Audit Associate and led audit engagements for both public and private companies in the banking, capital markets, and automotive leasing sectors. Mr. Knipper holds a Bachelor of Science in Business Administration and Accounting and a Master of Accountancy from Rider University.
- Luisa Ingargiola
Luisa Ingargiola自2017年2月起担任Avalon GloboCare Corp.（纳斯达克：ALTB）的首席财务官。Ingargiola女士自2020年12月起担任Vision Marine Technologies Inc.（纳斯达克：VMAR）董事兼审计委员会主席，自2018年4月起担任BioCorRx Inc.（OTCQB：BICX）董事兼审计委员会主席，自2025年2月起担任Fion Fuel Green PLC（纳斯达克：HTOO）董事，并在该公司董事会担任审计委员会（主席）、提名委员会及薪酬委员会成员，且自2021年6月起担任Dragonfly Energy Holdings Corp.（纳斯达克：DFLI）董事。此外，Ingargiola女士还曾于2018年5月至2022年11月担任AgEagle Aerial Systems Inc.（NYSE American：UAVS）董事兼审计委员会主席，于2020年12月至2021年12月担任Siyata Mobile董事兼审计委员会主席，并曾于2024年3月至2025年6月担任Xos, Inc.董事，于2018年3月至2024年3月（该公司被Xos收购期间）担任ElectraMeccanica Vehicles Corp.董事，以及于2020年11月至2023年2月担任Progress Acquisition Corp.董事。Ingargiola女士毕业于波士顿大学，获工商管理学士学位，主修金融专业，并拥有South Florida大学的健康管理硕士学位。
Luisa Ingargiola has served as Avalon Globocare Corp's Chief Strategy Officer since June 5, 2026. Ms Ingargiola served as Avalon Globocare Corp's Chief Financial Officer from February 21, 2017 to June 3, 2026. Ms. Ingargiola has significant experience serving as Chief Financial Officer or Audit Chair for multiple Nasdaq and New York Stock Exchange companies. She currently serves as Director and Audit Chair for several public companies, including Fusion Fuels (NASDAQ:HTOO), Dragonfly Energy (DFLI) and Vision Marine (VMAR), among others. She also sits on the Board of several Special Purpose Acquisition Corporations. From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then a member of the board of directors at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola graduated in 1989 from Boston University with a Bachelor's degree in Business Administration and a concentration in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida.- Luisa Ingargiola自2017年2月起担任Avalon GloboCare Corp.（纳斯达克：ALTB）的首席财务官。Ingargiola女士自2020年12月起担任Vision Marine Technologies Inc.（纳斯达克：VMAR）董事兼审计委员会主席，自2018年4月起担任BioCorRx Inc.（OTCQB：BICX）董事兼审计委员会主席，自2025年2月起担任Fion Fuel Green PLC（纳斯达克：HTOO）董事，并在该公司董事会担任审计委员会（主席）、提名委员会及薪酬委员会成员，且自2021年6月起担任Dragonfly Energy Holdings Corp.（纳斯达克：DFLI）董事。此外，Ingargiola女士还曾于2018年5月至2022年11月担任AgEagle Aerial Systems Inc.（NYSE American：UAVS）董事兼审计委员会主席，于2020年12月至2021年12月担任Siyata Mobile董事兼审计委员会主席，并曾于2024年3月至2025年6月担任Xos, Inc.董事，于2018年3月至2024年3月（该公司被Xos收购期间）担任ElectraMeccanica Vehicles Corp.董事，以及于2020年11月至2023年2月担任Progress Acquisition Corp.董事。Ingargiola女士毕业于波士顿大学，获工商管理学士学位，主修金融专业，并拥有South Florida大学的健康管理硕士学位。
- Luisa Ingargiola has served as Avalon Globocare Corp's Chief Strategy Officer since June 5, 2026. Ms Ingargiola served as Avalon Globocare Corp's Chief Financial Officer from February 21, 2017 to June 3, 2026. Ms. Ingargiola has significant experience serving as Chief Financial Officer or Audit Chair for multiple Nasdaq and New York Stock Exchange companies. She currently serves as Director and Audit Chair for several public companies, including Fusion Fuels (NASDAQ:HTOO), Dragonfly Energy (DFLI) and Vision Marine (VMAR), among others. She also sits on the Board of several Special Purpose Acquisition Corporations. From 2007 through 2016, Ms. Ingargiola served as the Chief Financial Officer and then a member of the board of directors at MagneGas Corporation (Nasdaq: MNGA). Prior to 2007, Ms. Ingargiola held various roles as Budget Director and Investment Analyst in several private companies. Ms. Ingargiola graduated in 1989 from Boston University with a Bachelor's degree in Business Administration and a concentration in Finance. In 1996, she received her MBA in Health Administration from the University of South Florida.